Cross section measurements in the main injector particle production (FNAL-E907) experiment at 58 GeV energy

Cross-sections are presented for 58 GeV {pi}, K, and p on a wide range of nuclear targets. These cross-sections are essential for determining the neutrino flux in measurements of neutrino cross-sections and oscillations. The E907 Main Injector Particle Production (MIPP) experiment at Fermilab is a fixed target experiment for measuring hadronic particle production using primary 120 GeV/c protons and secondary {pi}, K, and p beams. The particle identification is made by dE/dx in a time projection chamber, and by time-of-flight, differential Cherenkov and ring imaging Cherenkov detectors, which together cover a wide range of momentum from 0.1 GeV/c up to 120 GeV/c. MIPP targets span the periodic table, from hydrogen to uranium, including beryllium and carbon. The MIPP has collected {approx} 0.26 x 10{sup 6} events of 58 GeV/c secondary particles produced by protons from the main injector striking a carbon target

CROSS SECTION MEASUREMENTS IN THE MAIN INJECTOR PARTICLE PRODUCTION (FNAL-E907) EXPERIMENT AT 58 GEV ENERGY

Cross-sections are presented for 58 GeV {pi}, K, and p on a wide range of nuclear targets. These cross-sections are essential for determining the neutrino flux in measurements of neutrino cross-sections and oscillations. The E907 Main Injector Particle Production (MIPP) experiment at Fermilab is a fixed target experiment for measuring hadronic particle production using primary 120 GeV/c protons and secondary {pi}, K, and p beams. The particle identification is made by dE/dx in a time projection chamber, and by time-of-flight, differential Cherenkov and ring imaging Cherenkov detectors, which together cover a wide range of momentum from 0.1 GeV/c up to 120 GeV/c. MIPP targets span the periodic table, from hydrogen to uranium, including beryllium and carbon. The MIPP has collected {approx} 0.26 x 10{sup 6} events of 58 GeV/c secondary particles produced by protons from the main injector striking a carbon target

RESONANCE PRODUCTION OF EXCITED u QUARK AT FCC-BASED gamma p COLLIDERS

WOS: 000447741300002Several Beyond the Standard Model theories proposed that fermions might have composite substructure. The existence of excited quarks is going to be the noticeable proof for the compositeness of Standard Model fermions. For this reason, excited quarks have been investigated by phenomenological and experimental high-energy physicists at various collider options for the last few decades. The Future Circular Collider (FCC) has been recently planned as particle accelerator to be established at CERN. Beside the root s = 100 TeV proton-proton collisions, the FCC includes electron-positron and electron-proton collision options. Construction of linear e (-) e(+) colliders (or dedicated e-linac) tangential to the FCC will afford an opportunity to handle multi-TeV ep and gamma p collisions. In this respect, we executed a simulation of the resonance production of the excited u quark at the FCC-based gamma p colliders with choosing both the polarized and unpolarized photon beams. The findings revealed that the chirality structure of the q*-q-gamma vertex can be determined by the photon beam polarization. The attainable mass limits of the excited u quark reached the highest values when the polarized photon beam was chosen. In addition, the ultimate compositeness scale values can be handled by appropriate choice of the photon beam polarization.TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [114F337]This study is supported by TUBITAK under the grant No. 114F337. We thank Professor Yasar Onel for his support and contribution for encouraging such a research

Salvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncology

Background: We aimed to evaluate prognostic factors and response rates to various treatment approaches to patients with synovial sarcoma in an advanced setting. Materials and Methods: We retrospectively reviewed the medical records of 55 patients (18 pts; 32.7% women) diagnosed with synovial sarcomas. Twenty had metastatic disease at the time of diagnosis while the remainder of the study group consisted of patients who developed metastatic or inoperable locally advanced disease during follow up. Results: The median follow up time was 15 months (range: 1-53). Regarding outcomes for the 55 patients, 3 and 5 year overall survival rates were 26% and 14%, respectively. In univariate analyses among demographic factors female gender was associated with a better outcome (p=0.030). Patients with early progressing disease (<2 years) had a worse prognosis when compared to patient group with late relapse, but this difference did not reach statistical significance (p=0.056). According to multivariate Cox regression analysis patients who had undergone metastasectomy had a significant survival advantage (p=0.044). The overall response rate to different salvage chemotherapy regimens given as second line treatment was around 42.9-53.9% for all regimes. There were no statistically significant differences between chemotherapy regimens given in either second or third line settings in terms of overall survival. Conclusions: We observed no major differences in terms of response rate and survival between different salvage chemotherapy regimens. Although metastatic disease still carries a poor prognosis, metastasectomy was found to be associated with improved surviva

Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.

...American Society of Clinical Oncolog

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC). Patients and Methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis. Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS. Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC